Your SSRI Isn't Working. Your Genes May Be Why.

Your CYP2D6 gene encodes an enzyme that sits in your liver and does one job: break down and clear a huge fraction of psychiatric medications. SSRIs, SNRIs, tricyclic antidepressants, antipsychotics, opioids, beta-blockers. All of them depend on CYP2D6 to be metabolized and eliminated. If this enzyme is working well, your body maintains a steady, therapeutic level of the drug. If it’s not, you either build up toxic levels or never reach therapeutic levels at all.

Common variants in CYP2D6 like *2, *4, *10, and *17, as well as gene duplications, can make you a poor metabolizer or an ultra-rapid metabolizer. Roughly 7-10% of people with European ancestry are poor metabolizers. For those people, the standard SSRI dose accumulates to levels that can cause severe side effects, toxicity, or paradoxical worsening of mood and anxiety. Ultra-rapid metabolizers are the opposite problem: they clear the drug so quickly that therapeutic levels are never reached.

If you have the poor metabolizer variants, you might experience severe tremor, excessive sweating, sexual dysfunction, or emotional blunting at doses that your doctor considers ‘normal.’ You might feel worse on an SSRI than you did off it. You might develop side effects that seem disproportionate to the dose. Your doctor may interpret this as the drug ‘not being right for you,’ when actually your body is processing it too slowly.

CYP2C19 is your second major antidepressant processor. Several SSRIs, including citalopram and escitalopram, depend heavily on CYP2C19 for metabolism. So do some other psychiatric drugs, anxiety medications, and proton pump inhibitors (acid reflux drugs). Variants like *2 and *3 make you a poor metabolizer; *17 makes you a rapid metabolizer. Roughly 2-15% of people, depending on ancestry, are poor metabolizers for CYP2C19.

If you carry the poor metabolizer variants, citalopram or escitalopram will accumulate in your system. This can cause excessive sedation, sexual dysfunction, tremor, or even QT prolongation (a heart rhythm problem) at standard doses. The drug lingers in your blood much longer than intended. Your psychiatrist may think you need a lower dose or a different medication when actually your genes just need a dose adjustment.

You might describe this as ‘I felt awful on escitalopram even at the lowest dose,’ or ‘I switched to sertraline because citalopram made me feel drugged.’ That’s often a CYP2C19 story. You weren’t responding to the medication class. You were responding to a dose that was too high for your metabolizer status.

CYP2C9 is best known for metabolizing warfarin (a blood thinner) and NSAIDs. But it also processes some tricyclic antidepressants and other psychiatric medications. Variants like *2 and *3 reduce enzyme activity. Roughly 5-10% of people with European ancestry are poor metabolizers. This gene is less directly involved in SSRI metabolism than CYP2D6 or CYP2C19, but it becomes relevant if you’re on a tricyclic or if you’re taking NSAIDs alongside your psychiatric medication.

If you’re a poor CYP2C9 metabolizer, NSAIDs and older antidepressants will accumulate. You’re at higher risk of drug interactions, side effects, and toxicity when combining medications that depend on this enzyme. Your psychiatrist may not know this, especially if they’re not coordinating closely with your primary care doctor about all your medications.

You might notice that ibuprofen or naproxen gives you unusual side effects, or that adding an old-generation antidepressant felt disproportionately strong. That’s often a CYP2C9 problem, not a personal sensitivity to these drugs.

SLCO1B1 doesn’t break down drugs itself. Instead, it controls whether drugs can even get into your liver cells where they’ll be metabolized. Think of it as a bouncer at a nightclub: it decides which molecules get through the door. The *5 variant reduces this transporter’s activity. Roughly 15% of people carry this variant, especially those with European ancestry. This matters most for statins, but it also affects how some psychiatric medications and supplements are processed.

If you have the SLCO1B1 *5 variant, drugs that depend on active hepatic uptake will accumulate in your bloodstream instead of being cleared by your liver. You get higher systemic drug levels from standard doses than people with normal SLCO1B1. This increases your risk of side effects and toxicity, even if your metabolizing enzymes (CYP2D6, CYP2C19) are normal.

You might notice that psychiatric medications or supplements hit you harder than they hit other people. You might need lower doses than your doctor expects. Or you might experience side effects that seem out of proportion to the dose. This transporter variant is often overlooked in psychiatric prescribing, but it’s just as important as your metabolizer status.

VKORC1 encodes the vitamin K epoxide reductase enzyme. It controls the vitamin K recycling cycle in your cells, which is important for blood clotting and also for cellular methylation and detoxification. The -1639G>A variant is common; roughly 40% of people with European ancestry carry the A allele. This variant doesn’t directly metabolize SSRIs, but it affects the broader metabolic environment in which antidepressants function.

People with the VKORC1 A allele have reduced vitamin K recycling efficiency. This can subtly impair folate-dependent metabolic pathways, which include the production of neurotransmitter precursors and the clearing of metabolic byproducts that can accumulate in depression and anxiety. If you also have MTHFR variants (which many people do), the combined effect can be significant.

You might describe this as: ‘I feel like my antidepressant is fighting against a background of brain fog and low energy.’ Or: ‘The SSRI helps my mood a little, but I still can’t think clearly.’ That’s often a sign that your cellular methylation and detoxification are not fully supporting the medication.

MTHFR encodes methylenetetrahydrofolate reductase, the enzyme that converts dietary folate into the active form your cells use for methylation reactions. Methylation is fundamental to neurotransmitter synthesis, DNA repair, detoxification, and immune regulation. The C677T variant is extremely common; roughly 40% of people with European ancestry are heterozygous, and roughly 10-15% are homozygous. Both variants reduce enzyme efficiency.

If you have MTHFR C677T variants, your cells struggle to convert dietary folate into its active form. This impairs the production of serotonin precursors, dopamine, and the methyl groups needed for proper brain methylation, even if you’re eating plenty of folate-rich foods. Your SSRI may be working at the receptor level (blocking serotonin reuptake), but the underlying serotonin synthesis and recycling are compromised.

You might feel like your SSRI ‘works a little bit’ but never fully lifts your mood. Or you might have breakthrough anxiety or depression even on a therapeutic dose. Or you might struggle with fatigue and brain fog alongside your mood symptoms. These are classic signs of MTHFR-related impairment of the folate-dependent pathways that support mood.